Precision Oncology Market Size & Growth Forecast 2026–2035, By Segments (Product Type, End-use, Cancer Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Precision Oncology Market size was more than USD 122.26 Billion in 2025 and is set to grow at a 8.1% CAGR between 2026 and 2035, surpassing USD 266.4 Billion by 2035. The industry revenue for 2026 is calculated at USD 130.95 billion.
Get more details on this report
Request Free Sample ReportPrecision Oncology Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 46.64% share in 2025, supported by advanced genomic infrastructure, molecular diagnostics adoption, and integration of biomarker-driven treatment approaches.
- Asia Pacific is projected to expand at a 9.15% CAGR, driven by genomic profiling adoption, oncology investments, and wider access to specialized diagnostics.
Segment Momentum
- Therapeutics captured a 68.45% share in 2025 because targeted treatments remain central to patient management, with biomarker-informed prescribing driving sustained demand in routine oncology care.
- Pharmaceutical & Biotechnology Companies are the fastest-growing end-use segment as precision oncology becomes increasingly integrated into biomarker-driven drug development, companion diagnostics, and targeted clinical research.
Market Expansion Drivers
- Advancements in AI-powered diagnostics improving personalized cancer detection and treatment planning accuracy.
- Increasing approvals of targeted therapies accelerating adoption of personalized oncology treatment approaches.
- Expanding multi-cancer early detection programs strengthening demand for precision diagnostic technologies.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Leading companies in the precision oncology market include Thermo Fisher Scientific Inc. (USA), Illumina Inc. (USA), Qiagen N.V. (Germany), Exact Sciences Corporation (USA), Guardant Health Inc. (USA), Laboratory Corporation of America Holdings (USA), Roche Holding AG (Switzerland), Foundation Medicine Inc. (USA), Tempus Labs Inc. (USA), BioNTech SE (Germany).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
AI-enabled pathology, imaging, and genomic interpretation tools are reshaping clinical decision-making in the precision oncology market by reducing the time and uncertainty involved in identifying actionable biomarkers and matching patients to appropriate therapies. As algorithms improve pattern recognition across complex molecular and clinical datasets, oncologists gain more confidence in treatment selection, which supports broader use of comprehensive profiling and integrated diagnostic workflows. This is driving demand for the precision oncology market by making personalized care pathways more operationally feasible in routine oncology practice, especially where treatment choices depend on subtle genomic distinctions or rapid stratification.
Increasing approvals of targeted therapies accelerating adoption of personalized oncology treatment approaches
Rising approvals of biomarker-linked drugs are changing treatment pathways in the precision oncology market because each new targeted therapy increases the clinical value of testing for specific mutations, fusions, or expression profiles before therapy begins. Hospitals, cancer centers, and oncology networks respond by embedding molecular diagnostics more deeply into care protocols, since treatment eligibility and reimbursement increasingly depend on precise patient identification. This strengthens market development by linking diagnostic utilization directly to prescribing decisions, creating a tighter relationship between companion diagnostics, genomic testing platforms, and therapeutic uptake.
Expanding multi-cancer early detection programs strengthening demand for precision diagnostic technologies
As multi-cancer early detection initiatives expand, the precision oncology market is seeing stronger interest in highly sensitive assays capable of identifying molecular signals before disease becomes clinically obvious. These programs push providers and health systems to invest in advanced sequencing, liquid biopsy, and data interpretation capabilities that can distinguish early cancer signatures with enough specificity to guide follow-up action. That shift is increasing market penetration for precision diagnostic platforms because early detection is no longer limited to finding cancer alone; it increasingly requires molecular characterization that can inform confirmatory testing, risk stratification, and subsequent treatment planning.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Advancements in AI-powered diagnostics improving personalized cancer detection and treatment planning accuracy | 2.00% | High | North America, Europe | High | Mid Term |
| Increasing approvals of targeted therapies accelerating adoption of personalized oncology treatment approaches | 1.80% | High | North America, Asia Pacific | High | Near Term |
| Expanding multi-cancer early detection programs strengthening demand for precision diagnostic technologies | 1.50% | High | North America, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading regional position in 2025, accounting for a 46.64% share of the precision oncology market. This leadership is sustained by the region’s advanced molecular diagnostics infrastructure, broad availability of genomic testing, and established integration of biomarker-driven treatment selection into clinical practice. Market activity is also reinforced by strong pharmaceutical and biotechnology involvement in targeted therapy development, along with the routine use of companion diagnostics in oncology care, which keeps testing volumes and treatment adoption elevated across major care settings.
Asia Pacific is projected to expand at a 9.15% CAGR over the forecast period in the precision oncology market, driven by the accelerating adoption of genomic profiling and improving access to specialized cancer diagnostics across major healthcare systems. Growth is being impelled by rising investment in oncology capabilities, expanding use of precision-guided treatment pathways, and a larger patient base moving into more advanced diagnostic workflows. As hospitals and cancer centers incorporate molecular testing more consistently into treatment decisions, regional demand is increasing in a way that directly supports faster market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Molecular Diagnostics AdoptionGermany strengthens precision oncology through expanded use of molecular diagnostics and structured clinical decision-making. Healthcare institutions increasingly incorporate biomarker-guided treatment strategies to improve personalized cancer management.
France 🇫🇷
Collaborative Cancer NetworksFrance advances precision oncology through coordinated cancer networks that facilitate access to molecular testing and personalized therapies. Multidisciplinary collaboration helps translate genomic insights into practical clinical treatment strategies.
Italy 🇮🇹
Personalized Treatment ExpansionItaly continues expanding precision oncology by increasing adoption of genomic diagnostics and biomarker-guided therapeutic selection. Healthcare providers focus on strengthening specialist capabilities that support individualized cancer treatment across clinical settings.
Japan 🇯🇵
Biomarker-Based TreatmentJapan focuses on integrating genomic profiling with precision oncology treatment planning across multiple cancer types. Continued investment in advanced diagnostics and clinical research supports broader implementation of personalized therapeutic approaches.
South Korea 🇰🇷
Digital Oncology IntegrationSouth Korea combines advanced molecular diagnostics with digital healthcare capabilities to strengthen precision oncology practices. Growing collaboration between hospitals and biotechnology innovators supports more efficient personalized cancer treatment workflows.
United States 🇺🇸
Genomic Care IntegrationThe U.S. precision oncology market benefits from widespread integration of genomic testing, biomarker analysis, and targeted therapies into routine cancer care. Strong collaboration among healthcare providers, laboratories, and biotechnology companies supports personalized treatment decisions.
Segment Leadership and Growth Trends
Precision Oncology Market Share (%), Product Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTherapeutics held the leading position in the precision oncology market in 2025, accounting for a 68.45% share. This leadership is underpinned by the direct clinical role of targeted therapies and related treatment approaches in patient management, where revenue concentration is naturally higher because these products remain central to ongoing cancer care decisions. The precision oncology market continues to rely heavily on therapeutics as biomarker-informed treatment selection becomes part of routine oncology practice, reinforcing demand through real-world prescribing and the need for individualized intervention.
Diagnostics is the fastest-growing product type in the precision oncology market because treatment decisions increasingly depend on accurate molecular profiling before therapy begins. Growth is being influenced by the practical need to identify actionable mutations, stratify patients more precisely, and support therapy matching as oncology care becomes more data-driven. Compared with therapeutics, diagnostics is gaining momentum from its expanding role across earlier decision points in the care pathway, making it a critical enabler of precision-based clinical adoption.
End-use Segment Analysis: Hospitals & Diagnostic Laboratories (Largest Segment) vs Pharmaceutical & Biotechnology Companies (Fastest-Growing Segment)
In 2025, Hospitals & Diagnostic Laboratories represented the largest end-use segment in the precision oncology market, with a 49.61% share. Their leadership reflects the fact that these settings handle the core operational flow of cancer diagnosis, biomarker testing, and treatment planning, placing them at the center of precision oncology delivery. The precision oncology market depends on hospitals and diagnostic laboratories for routine patient access, sample processing, and integration of test results into clinical decisions, which sustains their dominant share.
Pharmaceutical & Biotechnology Companies are emerging as the fastest-growing end-use segment in the precision oncology market as drug development becomes increasingly tied to biomarker-defined patient populations. Their momentum is aided by the growing need to align clinical research with molecular targeting, companion diagnostic strategies, and more selective trial design. Relative to provider-based settings, these companies are seeing faster expansion because precision oncology is becoming more embedded in development pipelines rather than being used only at the point of care.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product Type | Diagnostics, Therapeutics | Therapeutics | Diagnostics |
| End-use | Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Healthcare Data Companies | Hospitals & Diagnostic Laboratories | Pharmaceutical & Biotechnology Companies |
| Cancer Type | Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer, Others | Breast Cancer | Cervical Cancer |
Competitive Landscape and Market Positioning
1. Thermo Fisher Scientific Inc. (USA)
2. Illumina Inc. (USA)
3. Qiagen N.V. (Germany)
4. Exact Sciences Corporation (USA)
5. Guardant Health Inc. (USA)
6. Laboratory Corporation of America Holdings (USA)
7. Roche Holding AG (Switzerland)
8. Foundation Medicine Inc. (USA)
9. Tempus Labs Inc. (USA)
10. BioNTech SE (Germany)
The precision oncology market is evolving through rapid advancements in biomarker discovery, targeted therapeutics, and genomic profiling technologies. Market participants are prioritizing investments in personalized cancer treatment platforms and companion diagnostics to improve clinical outcomes and treatment accuracy. Increasing focus on precision medicine integration and data-driven oncology research is also strengthening innovation across the market landscape.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Johnson & Johnson | Nov-25 | Johnson & Johnson acquired Halda Therapeutics for $3.05 billion to bolster its oncology pipeline. The transaction adds clinical-stage assets focused on prostate cancer and strengthens the company’s position in next-generation targeted cancer therapies, reflecting a strategic commitment to expanding its precision oncology portfolio through the acquisition of advanced therapeutic modalities. |
| Amgen | May-26 | Amgen completed an $840 million acquisition to secure a first-in-class acute myeloid leukemia (AML) therapy candidate. This transaction reinforces Amgen’s research focus on protein degradation and expands its precision oncology capabilities, supporting the accelerated development of targeted therapeutics designed to address unmet clinical needs in complex hematologic malignancies. |
| Clasp Therapeutics | May-24 | Clasp Therapeutics launched with $150 million in Series A financing co-led by Catalio Capital Management, Third Rock Ventures, and Novo Holdings. The company utilizes a proprietary platform to develop next-generation T-cell engagers targeting specific oncogenic driver mutations, aiming to enhance treatment precision and minimize off-target effects in personalized cancer care. |
| One Biosciences | Jul-25 | One Biosciences secured €15 million in funding to advance its OneMap single-cell oncology platform. The investment accelerates the development of AI-driven tumor profiling and high-resolution cancer characterization tools, intended to improve patient stratification and facilitate more accurate, data-backed therapeutic decision-making in clinical oncology settings. |
| Labcorp | Mar-26 | Labcorp expanded its strategic partnership with Illumina to co-develop and commercialize distributed next-generation sequencing in vitro diagnostic tests. By integrating liquid biopsy and tissue-based assays into clinical and laboratory networks, the collaboration aims to scale genomic testing infrastructure and broaden patient access to essential oncology biomarkers for precision diagnostics. |
| Guardant Health | Jan-26 | Guardant Health entered a multi-year partnership with Merck to develop companion diagnostics for oncology therapies. By leveraging liquid biopsy and genomic testing capabilities, the collaboration focuses on improving patient selection for clinical trials and enhancing the precision of treatment targeting across Merck's oncology drug development pipeline. |
| SOPHiA GENETICS | Jan-26 | SOPHiA GENETICS partnered with MD Anderson Cancer Center to deploy AI-powered multimodal analytics for precision oncology research. The collaboration integrates genomic and clinical datasets to improve predictive modeling and accelerate the translation of research findings into personalized cancer treatment strategies, enhancing research workflows through advanced artificial intelligence tools. |
| ImCheck Therapeutics | Aug-24 | ImCheck Therapeutics was awarded €20.18 million in non-dilutive funding via the France 2030 Plan’s "i-Démo" initiative. This capital supports the clinical advancement of the company’s lead candidate, ICT01, a γ9δ2 T-cell activating antibody currently in Phase I/IIa trials, accelerating the development of novel immunotherapeutic approaches for cancer treatment. |
| Blank Bio | May-26 | Blank Bio secured $7.2 million in seed funding and partnered with Pacific Biosciences to advance AI-driven RNA foundation models. The collaboration focuses on developing computational oncology platforms to enhance cancer target discovery and molecular profiling, strengthening the company’s technological capabilities in next-generation precision diagnostics and therapeutic research. |
| Bayer | Mar-24 | Bayer established a multi-year research collaboration with Aignostics to identify novel oncology drug targets. The partnership utilizes AI-driven pathology analysis and computational disease linkage to integrate biological datasets, aiming to increase translational research efficiency and accelerate the discovery of targeted precision oncology therapies. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Precision Oncology Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Precision Oncology Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the precision oncology market?
What is the projected value of the precision oncology industry by 2035?
How are AI-powered diagnostics accelerating adoption of precision oncology workflows?
How are targeted therapy approvals influencing demand for precision oncology technologies?
Why do Therapeutics hold the largest share of the precision oncology market?
Which end-use segment is growing fastest in the precision oncology market?
What factors make North America the leading precision oncology market?
How is Asia Pacific accelerating precision oncology adoption?
Who are the leading players in the precision oncology landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization